The researchers found that EvoETR was able to silence the PCSK9 gene in a highly specific and durable manner, thereby reducing plasma levels of PCSK9 protein and thereby regulating cholesterol metabolism, providing a new strategy for the treatment of hypercholesterolemia and related cardiovascular diseases. This evidence concerns the gene PCSK9 and cardiovascular disorder.